- Secured $500k non-dilutive funding from multiple innovation awards and competitions.- Established strategic partnerships with mid- to large-sized biopharma- Led, planned, executed, and successfully completed 4 pilot studies across hematology, immuno-oncology (melanoma), and infectious diseases (sepsis & COVID-19)- Led technology development from idealization to prototype generation (entering clinical validation).- Led strategic IP portfolio planning with the tech transfer office and external patent attorney.- Led business development through KOL interviews, clinicians, and biopharma liaison.- Led commercialization through QMS establishment, reimbursement strategy, and market access planning.

- Developed a liquid biopsy biomarker discovery platform using machine learning coupled nanoparticle multi-color flow-based extracellular vesicles (EVs) multi-omics- Pilot clinical study design, execution, and analysis using machine learning pipelines for diagnostic biomarker discovery in liquid biopsy.- Completed entrepreneurial modules from BioEntrepreneurship & Innovation Hub (University of Zurich)

- Deep investigation EVs mediated B cell maturation regulation through non-coding RNA transfer- Circulating EVs as novel predictive biomarkers in COVID-19 patients using flow cytometric analysis- Establishment of high-throughput flow-based immune EVs repertoire profiling technique

- Sales network establishment- Manufacturing pipeline assembly (HACCP)- Product owner

- Generation of T/B Lymphocytes from Embryonic or Hematopoietic Stem Cells in vitro- CRISPR-Cas9 overexpress/knockdown myelopoietic- and epigenetic-related genes in cell lines followed by western blot and RT-qPCR validation and quantification- Colony forming assay to investigate differentiation and proliferation differences in wild-type and Wnt-signaling-related gene knockout in hematopoietic stem cells